Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Bill Sutherland
BENC
Bill Sutherland
Benchmark Co.
Wall Street Analyst
★★☆☆☆
#1976
on 13Foresight · ranked by our own returns
44%
Success Rate
-2.3%
Average Return
8 of 18 calls profitable · -12.2% vs benchmark
📈 Across the calls we could measure, roughly 44% of Bill Sutherland's ratings turned a profit when each position was held for 1 year — averaging -2.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

47 Buy 11 Hold 0 Sell
Bill's Stock Coverage 21 ratings · 2026-06-20
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
HURN
Huron Consulting
 Jun 16, 2026 BUY Strong Buy
+72.4% avg upside
7 analysts
$215.00
137.38% Upside
 -1.4%
PRE
Prenetics Group
 Jun 16, 2026 BUY Buy
+17.7% avg upside
12 analysts
$30.00
46.36% Upside
 ·
AGL
Agilon Health
 May 21, 2026 BUY Buy
-59.5% avg upside
26 analysts
$95.00
16.47% Downside
 +41.2%
BEAT
HeartBeam
 May 15, 2026 BUY Buy
+454.2% avg upside
13 analysts
$5.00
558.16% Upside
 -18.5%
CCRN
Cross Country Healthcare
 May 08, 2026 HOLD Hold
+20.0% avg upside
15 analysts
 — -0.7%
HCSG
Healthcare Services
 Apr 23, 2026 BUY Buy
+5.5% avg upside
12 analysts
$30.00
30.79% Upside
 -4.9%
RCMT
Rcm Technologies
 Apr 08, 2026 BUY Strong Buy
+30.1% avg upside
3 analysts
$36.00
36.56% Upside
 -23.7%
CXW
CoreCivic
 Mar 24, 2026 BUY Strong Buy
+3.4% avg upside
10 analysts
$28.00
3.03% Downside
 +6.8%
NUTX
Clinigence Holdings
 Mar 10, 2026 BUY Strong Buy
+27.2% avg upside
4 analysts
$300.00
99.31% Upside
 +32.1%
SEM
Select Medical
 Mar 04, 2026 HOLD Buy
+28.1% avg upside
9 analysts
 — +2.9%
SGRY
Surgery Partners
 Mar 04, 2026 BUY Strong Buy
+68.4% avg upside
18 analysts
$24.00
64.99% Upside
 +7.5%
OMCL
Omnicell
 Feb 02, 2026 BUY Strong Buy
+35.7% avg upside
12 analysts
$60.00
53.60% Upside
 -11.5%
AMN
AMN Healthcare Services
 Nov 10, 2025 HOLD Buy
+35.2% avg upside
14 analysts
 — +64.5%
CCLD
CareCloud
 Nov 15, 2024 BUY Strong Buy
+282.7% avg upside
9 analysts
$4.50
106.38% Upside
 +26.7%
UPHL
UpHealth
 Sep 20, 2023 BUY Strong Buy
+2683233.4% avg upside
6 analysts
$7.00
2333233.38% Upside
 -87.8%
IONM
Assure Holdings
 May 23, 2023 BUY Strong Buy
+1599900.0% avg upside
2 analysts
$4.00
799900.03% Upside
 ·
OTRKQ
Ontrak
 Jan 17, 2023 HOLD Buy
+21716566.7% avg upside
7 analysts
 — ·
TAL
TAL Education Group
 Jul 26, 2021 HOLD Strong Buy
+155.6% avg upside
14 analysts
 — +12.3%
CREX
Creative Realities
 Jun 08, 2020 BUY Strong Buy
+41.1% avg upside
8 analysts
$5.00
26.81% Upside
 -38.6%
YCBD
cbdMD
 Dec 19, 2019 BUY Strong Buy
+604.9% avg upside
5 analysts
$7.00
872.25% Upside
 -8.4%
NRTSF
Nobilis Health
 Jan 03, 2019 BUY Strong Buy
+483333233.3% avg upside
3 analysts
$2.00
199999899.99% Upside
 ·
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Bill Sutherland — Frequently Asked Questions
How accurate are Bill Sutherland's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Bill's ratings were profitable over a one-year hold, with an average return of -2.3% per rating, or -12.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Bill ranked on 13Foresight?
Bill Sutherland is currently ranked #1976 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Bill cover?
Bill most recently has ratings on HURN, PRE, AGL, BEAT, CCRN, HCSG, RCMT, CXW, NUTX, SEM, SGRY, OMCL and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.